NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

When the proposed three-way deal was first announced earlier this year, it prompted debate about the antitrust implications in part because Catalent is working with many of Novo Nordisk's ...

Get the latest news and real-time alerts from Novo Nordisk A/S (NVO) stock at Seeking Alpha. Skip to content Home page Seeking Alpha - Power to Investors About Premium Explore Alpha Picks Home ...